EntryPoint Capital’s 89bio ETNB Stock Holding History

EntryPoint Capital’s Portfolio ETNB Stock Details ETNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,039	Closed	-$45.1K	–	1522
2023 Q4	$45.1K	Buy	+4,039	New	+$37.1K	0.04%	779

Other funds holding ETNB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

EntryPoint Capital's ETNB Position: Q1 2024 in Review

EntryPoint Capital sold out of 89bio (ETNB) in Q1 2024, closing a stake of 4,039 shares — an estimated $45.1K sold.

EntryPoint Capital first reported a position in ETNB in Q4 2023 and held it in 1 quarter. The position peaked at $45.1K in Q4 2023. 150 funds tracked by Wall St. Rank hold ETNB as of Q1 2024.

EntryPoint Capital reported no remaining 89bio position as of Q1 2024 after selling out during the quarter.
EntryPoint Capital sold 4,039 89bio shares in Q1 2024, an estimated $45.1K.
EntryPoint Capital first reported a position in 89bio in Q4 2023 and held it in 1 quarter.
EntryPoint Capital's 89bio position peaked at $45.1K in Q4 2023.
150 funds tracked by Wall St. Rank held 89bio as of Q1 2024.

Based on EntryPoint Capital's 13F filing for Q1 2024, filed 14 May 2024.